HealthLinx scores high with OvPlex
Monday, 08 December, 2008
Diagnostics company HealthLinx has reported increased efficiency of its ovarian cancer diagnostic OvPlex in a Phase II biomarker trial.
The trial showed a diagnostic efficiency of 98 per cent in the second-generation test. The first generation diagnostic, distributed by ARL Pathology, has an efficiency of 93 per cent.
The trial was aimed at testing the efficiency of the two new biomarkers added to the OvPlex panel, HTX005 and HTX010. The panel includes the gold standard CA125 biomarker.
The study used 107 samples, including 46 disease subjects and 61 controls. The company now intends to run a larger Phase II trial involving 350 disease samples plus controls across multiple sites, including Asia and Europe.
The second-generation test is expected to be ready late next year or in early 2010.
Air pollutant exposure linked to glaucoma, cataracts and suicide
People who are exposed to high levels of air pollution are more likely to develop glaucoma and...
Could this 'nanobone' material allow children to regrow bone?
Australian scientists believe they have found an alternative to invasive bone graft procedures in...
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
